Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biopsy
Combined Modality Therapy
Female
Humans
Kaplan-Meier Estimate
Lenalidomide
/ administration & dosage
Lymphoma, Follicular
/ diagnosis
Male
Middle Aged
Neoplasm Grading
Neoplasm Metastasis
Neoplasm Staging
Neoplasms, Second Primary
/ etiology
Rituximab
/ administration & dosage
Symptom Assessment
Time Factors
Tomography, X-Ray Computed
Treatment Outcome
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
25 07 2019
25 07 2019
Historique:
received:
11
10
2018
accepted:
03
04
2019
pubmed:
19
5
2019
medline:
15
1
2020
entrez:
19
5
2019
Statut:
ppublish
Résumé
The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab plus lenalidomide in untreated follicular lymphoma patients in need of systemic therapy. Patients were randomized to rituximab (375 mg/m
Identifiants
pubmed: 31101627
pii: S0006-4971(20)42383-3
doi: 10.1182/blood-2018-10-879643
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Lenalidomide
F0P408N6V4
Banques de données
ClinicalTrials.gov
['NCT01307605']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-362Informations de copyright
© 2019 by The American Society of Hematology.